ClinicalTrials.gg
CompletedNCT04338321ESCAPE-TRDUpdated Apr 29, 2025Results posted

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

A Phase 3 interventional study of Esketamine 28 mg and Esketamine 56 mg in Depressive Disorder, Major, sponsored by Janssen-Cilag International NV. Completed at 171 sites in 24 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
676
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.

Enrollment
Largest of 17
676 · median 147
Started
2020
with 2 others
Phase 3
7 of 17
2 open now
Registered
7th of 17
by date
Lead sponsor
1 of 17
Janssen-Cilag International NV

Among the 17 studies testing esketamine in Depressive Disorder, Major, this one has the largest enrollment, is one of 3 that started in 2020, is one of 7 in phase 3, and was the 7th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing esketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI), in achieving remission in participants who have treatment-resistant major depressive disorder (MDD) with a current moderate to severe depressive episode.

Read the detailed description

A depressive state with classical symptoms such as low (depressive/sad) mood, markedly diminished interest in activities, significant weight loss/gain, insomnia or hypersomnia, psychomotor agitation/retardation, excessive fatigue, inappropriate guilt, diminished concentration, and recurrent thoughts of death, persisting for more than 2 weeks is classified as major depressive disorder (MDD). The mechanism of action of ketamine is distinct from conventional antidepressants (ADs), which target the monoamines (serotonin, norepinephrine, and/or dopamine). Esketamine, the S-enantiomer of ketamine, is approved and widely used for the induction and maintenance of anesthesia via intramuscular or intravenous (IV) administration. There is a significant unmet need to develop novel AD treatments based on the relevant psychophysiological pathways underlying MDD. The goal of any novel treatment would be the rapid and long-lasting relief of depressive symptoms, especially in participants with treatment-resistant depression (TRD), who lack a sufficient response to the currently available treatment strategies. The study consists of a Screening Phase (up to 14 days), an Acute Phase (8 Weeks), a Maintenance Phase (24 Weeks) and a Safety Follow-up Phase (2 Weeks). Safety assessment includes adverse event, serious adverse events, physical examination, vital signs, electrocardiogram, clinical safety laboratory assessments, suicidal risk monitoring. The total duration of the study is approximately 36 Weeks for all participants.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At screening, each participant must meet , fifth edition (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) or recurrent MDD, without psychotic features, based on clinical assessment and confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • At screening and baseline, each participant must have an Inventory of Depressive Symptomatology - Clinician-rated, 30 item (IDS-C30) total score of greater than or equal to (>=) 34
  • Must be on a current antidepressive treatment that includes an selective serotonin reuptake inhibitor (SSRI)/ serotonin-norepinephrine reuptake inhibitor (SNRI) at screening that resulted in nonresponse (less than 25% improvement of symptoms) after having been given at an adequate dosage (based on antidepressive dosages from SmPC [or local equivalent, if applicable]) for an adequate duration of at least 6 weeks and having been uptitrated to the maximum tolerated dose; however, at screening the participant must show signs of minimal clinical improvement to be eligible for the study. Clinical improvement of a participant on their current AD treatment will be retrospectively evaluated in a qualified psychiatric interview performed by an experienced clinician. At baseline (Day 1) prior to randomization, the investigator will evaluate any changes in the participant's signs/symptoms of depression since the screening assessment and confirm that the inclusion criteria for the current AD treatment are still met (that is nonresponse and minimal clinical improvement)
  • The current antidepressive treatment, was immediately preceded by nonresponse to at least 1 but not more than 5 different, consecutive treatments (all within the current moderate to severe antidepressive episode) with anti-depressants (ADs) taken at an adequate dosage for an adequate duration of at least 6 weeks and must be documented
  • Must have been treated with at least 2 different antidepressive substance classes among the treatments taken at an adequate dosage for an adequate duration of at least 6 weeks resulting in nonresponse in the current moderate to severe depressive episode (including the current treatment with an selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor [SSRI/SNRI])
  • Must be on a single oral SSRI/SNRI on Day 1 prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Received treatment with esketamine or ketamine in the current moderate to severe depressive episode
  • Received treatment with quetiapine extended- or immediate-release in the current moderate to severe depressive episode of a dose higher than 50 milligram per day (mg/day)
  • Had depressive symptoms in the current moderate to severe depressive episode that previously did not respond to an adequate course of treatment with electroconvulsive therapy (ECT), defined as at least 7 treatments with unilateral/bilateral ECT
  • Has no signs of clinical improvement at all or with a significant improvement on their current AD treatment that includes an SSRI/SNRI as determined at screening by an experienced clinician during the qualified psychiatric interview
  • Received vagal nerve stimulation or has received deep brain stimulation in the current episode of depression
  • has a current or prior diagnosis of a psychotic disorder or MDD with psychotic features, bipolar or related disorders (confirmed by the Mini International Neuropsychiatric Interview [MINI]), obsessive compulsive disorder (current only), intellectual disability (DSM-5 diagnostic codes 317, 318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality disorder, or antisocial personality disorder, histrionic personality disorder, or narcissistic personality disorder
  • age at onset of first episode of MDD was more than or equal to (>=) 55 years
  • has homicidal ideation or intent, per the investigator's clinical judgment; or has suicidal ideation with some intent to act within 1 month prior to screening, per the investigator's clinical judgment; or based on the Columbia-Suicide Severity Rating Scale (C-SSRS), corresponding to a response of "Yes" on Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) for suicidal ideation, or a history of suicidal behavior within the past year prior to screening. Participants reporting suicidal ideation with intent to act or suicidal behavior prior to the start of the acute phase should also be excluded
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
676 participants (actual)

Study arms

  • Experimental
    Esketamine Arm

    Participants will receive treatment with esketamine nasal spray (28 milligram \[mg\] \[initial dose for elderly participants 65 to 74 years of age and adults of Japanese ancestry; may be used throughout the study in these populations; may be uptitrated in 28 mg increments\], 56 mg \[initial dose for adult participants aged 18 to 64 years and may be used for all age groups throughout the study\], or 84 mg \[maximum dose esketamine nasal spray may be uptitrated to\]) twice-weekly with a flexible dose regimen from Day 1 until Week 4, once weekly from Week 5 to Week 8 and once-weekly or once every 2 weeks from Week 9 to Week 32 in combination with continuing serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI).

    Drug: Esketamine 28 mg · Drug: Esketamine 56 mg · Drug: Esketamine 84 mg · Drug: SSRI/SNRI

  • Active comparator
    Comparator Arm

    Participants will continue to take their current SSRI/SNRI augmented with quetiapine extended release (XR) as per the Summary of Product Characteristics (SmPC) (or local equivalent, if applicable). In adult participants aged 18 to 64 years, the initial dose is 50 mg/day on Days 1-2, 150 mg/day on Days 3-4 \[lowest effective dose\]; a further dose increase to 300 mg/day on Day 5 and onward will be based on individual participant evaluation. In elderly participants aged 65 to 74 years, the initial dose is 50 mg/day on Days 1-3, 100 mg/day on Days 4-7, and 150 mg/day on Day 8; a further dose increase to 300 mg/day will be based on individual participant evaluation no earlier than Day 22.

    Drug: Quetiapine XR 50 mg · Drug: Quetiapine XR 100 mg · Drug: Quetiapine XR 150 mg · Drug: SSRI/SNRI

Interventions

  • Esketamine will be self-administered at a dose of 28 mg as nasal spray.

  • Esketamine will be self-administered at a dose of 56 mg as nasal spray.

  • Esketamine will be self-administered at a dose of 84 mg (maximum uptitrated dose) as nasal spray.

  • Quetiapine XR will be administered at an initial dose of 50 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.

  • Quetiapine XR will be administered at a dose of 100 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.

  • Quetiapine XR will be administered at a dose of 150 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.

  • DrugSSRI/SNRI

    Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the SmPC (or local equivalent, if applicable).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 8

    Percentage of participants with remission as assessed by the MADRS at Week 8 was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. A participant was defined as being in remission if the MADRS total score was less than or equal to (\<=)10 and no treatment or study discontinuation before Week 8.

    Time frame: Week 8

Secondary outcomes

  1. Percentage of Participants With Both Remission at Week 8 and Relapse-free Until Week 32

    Percentage of participants with both remission at Week 8 and relapse-free until Week 32 were reported. A participant was defined as being in remission if the MADRS total score was \<= 10 and no treatment or study discontinuation before Week 8. A relapse was defined by any of following: a) Worsening of depressive symptoms as indicated by MADRS total score greater than or equal to (\>=) 22 confirmed by 1 additional assessment of MADRS total score \>= 22 within the next 5 to 15 days. The date of the second MADRS assessment was used for the date of relapse; b) Any psychiatric hospitalization for: worsening of depression, suicide prevention or suicide attempt, the start date of hospitalization was the date of relapse; c) Suicide attempt, completed suicide, or any other clinically relevant event determined by investigator's judgment to be indicative of a relapse of depressive illness, but without hospitalized. The onset of the event was used for the date of relapse.

    Time frame: Week 32

  2. Change From Baseline in Clinician-rated Overall MADRS Score

    Change from baseline in clinician-rated overall MADRS score was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts.

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32

  3. Change From Baseline in Clinician-rated Overall MADRS Score at Last Observation Carried Forward (LOCF)

    Change from baseline in clinician-rated overall MADRS score at LOCF was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

    Time frame: Baseline, LOCF at Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32

  4. Change From Baseline in Clinician-rated Overall Severity of Depressive Illness as Assessed by Clinical Global Impression - Severity (CGI-S) Scale Score

    Change from baseline in clinician-rated overall severity of depressive illness as assessed by CGI-S scale score was reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Negative change in score indicates improvement.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32

  5. Change From Baseline in Clinician-rated Overall Severity of Depressive Illness as Assessed by CGI-S Scale Score at LOCF

    Change from Baseline in clinician-rated overall severity of depressive illness as assessed by CGI-S scale score at LOCF was reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. A participant is assessed on severity of mental illness at the time of rating according to: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

    Time frame: Baseline, LOCF at Weeks 2, 3, 4, 8, 12, 16, 20, 24, 28, 32

  6. Clinician-rated Overall Severity of Depressive Illness as Assessed by Clinical Global Impression - Change (CGI-C) Scale Score

    Clinician-rated overall severity of depressive illness as assessed by CGI-C scale score was reported. The CGI-C evaluates the total improvement whether or not entirely due to drug treatment on a scale of 1 to 7. Compared to the condition at baseline, a participant is assessed on how much he/she has changed, according to: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse. Higher scores indicate more severity.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32

  7. Number of Participants With Clinician-rated Overall Severity of Depressive Illness as Assessed by CGI-C Scale Score at LOCF

    Number of participants with clinician-rated overall severity of depressive illness as assessed by CGI-C scale score at LOCF was reported. The CGI-C evaluates the total improvement whether or not entirely due to drug treatment on a scale of 1 to 7. Compared to the condition at baseline, a participant is assessed on how much he/she has changed, according to: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse. Higher scores indicate more severity. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

    Time frame: Baseline, LOCF at Weeks 2, 3, 4, 8, 12, 16, 20, 24, 28, 32

  8. Change From Baseline in Participant-reported Depressive Symptoms as Assessed by Patient Health Questionnaire (PHQ) 9-item Total Score

    Change from baseline in participant-reported depressive symptoms as assessed by PHQ 9-item total score was reported. The PHQ-9 is a validated 9-item, patient-reported outcome (PRO) measure to assess depressive symptoms. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27).

    Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32

  9. Change From Baseline in Participant-reported Depressive Symptoms as Assessed by PHQ 9-item Total Score at LOCF

    Change from baseline in participant-reported depressive symptoms as assessed by PHQ 9-item total score at LOCF was reported. The PHQ-9 is a validated 9-item, PRO measure to assess depressive symptoms. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27). LOCF is defined as participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

    Time frame: Baseline, LOCF at Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32

  10. Change From Baseline in Participant-reported Functional Impairment and Associated Disability as Assessed by Sheehan Disability Scale (SDS) Total Score

    Change from baseline in participant-reported functional impairment and associated disability as assessed by SDS total score was reported. The SDS is a validated PRO measure consisting of a 5-item questionnaire that has been widely used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a rating scale from 0 to 10. It also has 1 item assessing days lost from school or work and 1 item assessing days of underproductivity. The scores for the first 3 items are summed to create a total score of 0 to 30, where higher score indicates greater impairment. Scores \<=2 for each item and \<= 6 for the total score are considered functional remission.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32

  11. Change From Baseline in Participant-reported Functional Impairment and Associated Disability as Assessed by SDS Total Score at LOCF

    Change from baseline in participant-reported functional impairment and associated disability as assessed by SDS total score at LOCF was reported. The SDS is a validated PRO measure consisting of a 5-item questionnaire for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a rating scale from 0 to 10. It also has 1 item assessing days lost from school or work and 1 item assessing days of underproductivity. The scores for the first 3 items are summed to create a total score of 0 to 30, where higher score indicates greater impairment. Scores \<=2 for each item and \<= 6 for the total score are considered functional remission. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

    Time frame: Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32

  12. Change From Baseline in Participant-reported Health-related Quality of Life (HRQoL) and Health Status as Assessed by 36-item Short-Form Health Survey (SF-36) Scale Score

    Change from baseline in participant-reported HRQoL and health status as assessed by SF-36 scale score was reported. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using likert-type responses (for example: none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQoL, 100=best HRQoL. Higher scores indicate better health status.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32

  13. Change From Baseline in Participant-reported HRQoL and Health Status as Assessed by SF-36 Scale Score at LOCF

    Change from baseline in participant-reported HRQoL and health status as assessed by SF-36 domain scores at LOCF was reported. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using likert-type responses (for example: none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQoL, 100=best HRQoL. Higher scores indicate better health status. LOCF is defined as participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

    Time frame: Baseline, LOCF at Weeks 8, 12, 16, 20, 24, 28, 32

  14. Change From Baseline in Participant-reported Quality of Life as Assessed by Quality of Life in Depression Scale (QLDS) Total Score

    Change from baseline in participant-reported quality of life as assessed by QLDS total score was reported. The QLDS is a disease-specific validated PRO measure which assesses the impact that depression has on a participant's quality of life. It is a 34-item self-rated questionnaire which consists of dichotomous response questions, with the response being either True/Not True. Each statement on the QLDS is given a score of "1" or "0". A score of "1" is indicative of adverse quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32

  15. Change From Baseline in Participant-reported Quality of Life as Assessed by QLDS Total Score at LOCF

    Change from baseline in participant-reported quality of life as assessed by QLDS total score at LOCF was reported. The QLDS is a disease-specific validated PRO measure which assesses the impact that depression has on a participant's quality of life. It is a 34-item self-rated questionnaire which consists of dichotomous response questions, with the response being either True/Not True. Each statement on the QLDS is given a score of "1" or "0". A score of "1" is indicative of adverse quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

    Time frame: Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32

  16. Change From Baseline in Participant-reported Health-related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score: Health Status Index

    Change from baseline in participant-reported health-related quality of Life as assessed by EQ-5D-5L score: health status index was reported. The EQ-5D-5L is a standardized 2-part instrument used to measure health outcomes, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ-VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today." Responses were used to generate health status index which ranges from 0 (dead) and 1 (full health), a lower score indicates worse health.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32

  17. Change From Baseline in Participant-reported Health-related Quality of Life Group, as Assessed by EQ-5D-5L Score: Health Status Index at LOCF

    Change from baseline in participant-reported health-related quality of Life as assessed by EQ-5D-5L score: health status index at LOCF was reported. The EQ-5D-5L is a standardized 2-part instrument used to measure health outcomes, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ-VAS. The EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today." LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

    Time frame: Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32

  18. Change From Baseline in Participant-reported Health Status as Assessed by EQ-5D-5L Score: VAS

    Change from baseline in participant-reported health status as assessed by EQ-5D-5L Score: VAS was reported. The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32

  19. Change From Baseline in Participant-reported Health Status as Assessed by EQ-5D-5L Score: VAS at LOCF

    Change from baseline in participant-reported health status as assessed by EQ-5D-5L score: VAS at LOCF was reported. The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

    Time frame: Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32

  20. Change From Baseline in Participant-reported Work Productivity as Assessed by Work Productivity and Activity Impairment (WPAI): Depression Questionnaire

    Change from baseline in participant-reported work productivity as assessed by WPAI: depression questionnaire was reported. The WPAI-D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores were derived only for respondents who were working (should be missing for non-working), but the last score was applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32

  21. Change From Baseline in Participant-reported Work Productivity as Assessed by WPAI: Depression Questionnaire at LOCF

    Change from baseline in participant-reported work productivity as assessed by WPAI: depression questionnaire at LOCF was reported. The WPAI-D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores were derived only for respondents who were working (should be missing for non-working), but the last score was applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

    Time frame: Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32

  22. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs were those events if they started after administration of the first dose until 14 days after the last dose of study medication for other TEAEs except serious; and first dose until 30 days after the last dose of study medication for serious TEAEs.

    Time frame: Up to Week 35

  23. Number of Participants With TEAEs of Special Interest

    Number of participants with TEAEs of special interest were reported. It included significant TEAEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Events such as sedation, depersonalization/derealization disorder, depression suicidal, aggression, allergic cystitis, cholestasis and jaundice of hepatic origin, and many more were considered as TEAEs of special interest.

    Time frame: Up to Week 35

  24. Number of Participants With Suicidal Ideation or Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    Number of participants with suicidal ideation or behavior as assessed by C-SSRS score was reported. The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Suicidal ideation consists of 5 items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, and active suicidal ideation with specific plan and intent. Suicidal behavior consists of 5 items: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt (non-fatal), and completed suicide. The maximum score (from the 10 categories) assigned for each participant was summarized into one of three broad categories: No suicidal ideation or behavior (0), Suicidal ideation (1 - 5), Suicidal behavior (6 - 10). Total score ranges from 1 to 10. Higher scores indicate more severe suicidal ideation and behavior.

    Time frame: Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32

07

Results

Posted Feb 15, 2023
Limitations and caveats
To minimize potential bias, the Montgomery-Asberg Depression Rating Scale (MADRS) was performed by an independent on-site rater who was blinded to the participant's treatment, and who was not involved in any other study assessments or treatment decisions.

Participant flow

Participant flow — Overall Study
MilestoneEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Started336340
Treated (safety analysis set)334336
Completed treatment258203
Completed274232
Not completed62108
Withdrew: Adverse event410
Withdrew: Death11
Withdrew: Lost to follow-up49
Withdrew: Withdrawal by subject4569
Withdrew: Physician decision59
Withdrew: Other310

Outcome measures

PrimaryPercentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 8

Percentage of participants with remission as assessed by the MADRS at Week 8 was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. A participant was defined as being in remission if the MADRS total score was less than or equal to (\<=)10 and no treatment or study discontinuation before Week 8.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 8
Percentage of participantsEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 827.117.6
Statistical analysis
  • Esketamine Nasal Spray + Oral Antidepressant (AD) vs Quetiapine Extended Release (XR) + Oral AD · Cochran-Mantel-Haenszel · p = =0.003 · Mean difference (final values): 9.44 · 95% CI 3.19 to 15.68
SecondaryPercentage of Participants With Both Remission at Week 8 and Relapse-free Until Week 32

Percentage of participants with both remission at Week 8 and relapse-free until Week 32 were reported. A participant was defined as being in remission if the MADRS total score was \<= 10 and no treatment or study discontinuation before Week 8. A relapse was defined by any of following: a) Worsening of depressive symptoms as indicated by MADRS total score greater than or equal to (\>=) 22 confirmed by 1 additional assessment of MADRS total score \>= 22 within the next 5 to 15 days. The date of the second MADRS assessment was used for the date of relapse; b) Any psychiatric hospitalization for: worsening of depression, suicide prevention or suicide attempt, the start date of hospitalization was the date of relapse; c) Suicide attempt, completed suicide, or any other clinically relevant event determined by investigator's judgment to be indicative of a relapse of depressive illness, but without hospitalized. The onset of the event was used for the date of relapse.

Time frame:
Week 32
Reported as:
Number · Percentage of Participants
Percentage of Participants With Both Remission at Week 8 and Relapse-free Until Week 32
Percentage of ParticipantsEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Percentage of Participants With Both Remission at Week 8 and Relapse-free Until Week 3221.714.1
SecondaryChange From Baseline in Clinician-rated Overall MADRS Score

Change from baseline in clinician-rated overall MADRS score was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts.

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Reported as:
Mean · Unit on scale
Change From Baseline in Clinician-rated Overall MADRS Score
Unit on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 1-5.3 ± 5.71-3.7 ± 4.65
Week 2-9.0 ± 6.87-6.1 ± 6.52
Week 4-12.8 ± 7.50-9.8 ± 7.32
Week 6-14.9 ± 8.27-12.2 ± 8.11
Week 8-16.4 ± 8.67-14.3 ± 8.26
Week 10-18.2 ± 8.32-16.2 ± 7.38
Week 12-18.4 ± 8.26-16.7 ± 8.16
Week 14-19.0 ± 8.06-17.1 ± 8.06
Week 16-19.6 ± 8.16-17.8 ± 8.23
Week 18-19.9 ± 8.59-18.1 ± 8.36
Week 20-20.1 ± 8.75-19.1 ± 8.11
Week 22-20.6 ± 8.32-19.5 ± 8.04
Week 24-21.0 ± 8.58-20.1 ± 7.96
Week 26-21.2 ± 8.19-20.0 ± 8.18
Week 28-21.5 ± 8.33-20.8 ± 8.33
Week 30-21.8 ± 8.66-20.6 ± 8.39
Week 32-22.2 ± 8.12-20.5 ± 8.58
SecondaryChange From Baseline in Clinician-rated Overall MADRS Score at Last Observation Carried Forward (LOCF)

Change from baseline in clinician-rated overall MADRS score at LOCF was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

Time frame:
Baseline, LOCF at Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Reported as:
Mean · Unit on scale
Change From Baseline in Clinician-rated Overall MADRS Score at Last Observation Carried Forward (LOCF)
Unit on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 2-9.0 ± 6.86-5.8 ± 6.53
Week 4-12.6 ± 7.63-8.9 ± 7.70
Week 6-14.5 ± 8.47-10.7 ± 8.78
Week 8-15.7 ± 9.07-12.0 ± 9.30
Week 10-16.9 ± 9.15-12.8 ± 9.24
Week 12-17.1 ± 9.22-13.1 ± 9.82
Week 14-17.6 ± 9.08-13.2 ± 9.88
Week 16-18.1 ± 9.24-13.7 ± 10.17
Week 18-18.1 ± 9.60-13.8 ± 10.26
Week 20-18.2 ± 9.80-14.3 ± 10.46
Week 22-18.7 ± 9.83-14.6 ± 10.56
Week 24-18.8 ± 9.88-14.8 ± 10.77
Week 26-19.0 ± 9.76-14.9 ± 10.76
Week 28-19.1 ± 9.88-15.2 ± 11.08
Week 30-19.2 ± 10.10-15.2 ± 11.11
Week 32-19.6 ± 9.94-15.1 ± 11.18
SecondaryChange From Baseline in Clinician-rated Overall Severity of Depressive Illness as Assessed by Clinical Global Impression - Severity (CGI-S) Scale Score

Change from baseline in clinician-rated overall severity of depressive illness as assessed by CGI-S scale score was reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Negative change in score indicates improvement.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on scale
Change From Baseline in Clinician-rated Overall Severity of Depressive Illness as Assessed by Clinical Global Impression - Severity (CGI-S) Scale Score
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 1-0.3 ± 0.58-0.2 ± 0.53
Week 2-0.7 ± 0.79-0.5 ± 0.77
Week 3-1.0 ± 0.88-0.7 ± 0.83
Week 4-1.3 ± 0.94-1.0 ± 0.95
Week 8-1.7 ± 0.98-1.4 ± 1.05
Week 12-1.9 ± 1.00-1.7 ± 1.07
Week 16-2.1 ± 1.05-1.9 ± 1.15
Week 20-2.2 ± 1.04-2.0 ± 1.22
Week 24-2.3 ± 1.06-2.1 ± 1.22
Week 28-2.4 ± 1.02-2.2 ± 1.19
Week 32-2.5 ± 1.05-2.3 ± 1.21
SecondaryChange From Baseline in Clinician-rated Overall Severity of Depressive Illness as Assessed by CGI-S Scale Score at LOCF

Change from Baseline in clinician-rated overall severity of depressive illness as assessed by CGI-S scale score at LOCF was reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. A participant is assessed on severity of mental illness at the time of rating according to: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

Time frame:
Baseline, LOCF at Weeks 2, 3, 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on scale
Change From Baseline in Clinician-rated Overall Severity of Depressive Illness as Assessed by CGI-S Scale Score at LOCF
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 2-0.7 ± 0.79-0.5 ± 0.75
Week 3-1.0 ± 0.88-0.7 ± 0.84
Week 4-1.3 ± 0.95-0.9 ± 0.96
Week 8-1.6 ± 1.02-1.2 ± 1.10
Week 12-1.8 ± 1.09-1.3 ± 1.18
Week 16-1.9 ± 1.16-1.4 ± 1.26
Week 20-2.0 ± 1.17-1.5 ± 1.32
Week 24-2.1 ± 1.22-1.5 ± 1.35
Week 28-2.1 ± 1.22-1.6 ± 1.36
Week 32-2.2 ± 1.27-1.6 ± 1.40
SecondaryClinician-rated Overall Severity of Depressive Illness as Assessed by Clinical Global Impression - Change (CGI-C) Scale Score

Clinician-rated overall severity of depressive illness as assessed by CGI-C scale score was reported. The CGI-C evaluates the total improvement whether or not entirely due to drug treatment on a scale of 1 to 7. Compared to the condition at baseline, a participant is assessed on how much he/she has changed, according to: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse. Higher scores indicate more severity.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on scale
Clinician-rated Overall Severity of Depressive Illness as Assessed by Clinical Global Impression - Change (CGI-C) Scale Score
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 13.3 ± 0.773.6 ± 0.72
Week 22.9 ± 0.873.3 ± 0.85
Week 32.7 ± 0.833.1 ± 0.84
Week 42.4 ± 0.852.9 ± 0.96
Week 82.1 ± 0.842.4 ± 0.93
Week 122.0 ± 0.852.3 ± 0.89
Week 161.9 ± 0.872.2 ± 0.99
Week 201.8 ± 0.852.1 ± 0.92
Week 241.8 ± 0.852.0 ± 0.84
Week 281.7 ± 0.842.0 ± 0.91
Week 321.6 ± 0.811.9 ± 0.88
SecondaryNumber of Participants With Clinician-rated Overall Severity of Depressive Illness as Assessed by CGI-C Scale Score at LOCF

Number of participants with clinician-rated overall severity of depressive illness as assessed by CGI-C scale score at LOCF was reported. The CGI-C evaluates the total improvement whether or not entirely due to drug treatment on a scale of 1 to 7. Compared to the condition at baseline, a participant is assessed on how much he/she has changed, according to: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse. Higher scores indicate more severity. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

Time frame:
Baseline, LOCF at Weeks 2, 3, 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Count of participants · Participants
Number of Participants With Clinician-rated Overall Severity of Depressive Illness as Assessed by CGI-C Scale Score at LOCF
ParticipantsEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Very much improved at Week 264
Much improved at Week 29739
Minimally improved at Week 2141149
No change at Week 275108
Minimally worse at Week 2626
Much worse at Week 215
Very much worse at Week 210
Very much improved at Week 3148
Much improved at Week 312657
Minimally improved at Week 3135159
No change at Week 34581
Minimally worse at Week 3620
Much worse at Week 306
Very much worse at Week 310
Very much improved at Week 44117
Much improved at Week 415083
Minimally improved at Week 4102152
No change at Week 42952
Minimally worse at Week 4417
Much worse at Week 4010
Very much worse at Week 410
Very much improved at Week 86838
Much improved at Week 8165118
Minimally improved at Week 868105
No change at Week 81844
Minimally worse at Week 8516
Much worse at Week 8210
Very much worse at Week 810
Very much improved at Week 128345
Much improved at Week 12156120
Minimally improved at Week 125392
No change at Week 122447
Minimally worse at Week 12918
Much worse at Week 1219
Very much worse at Week 1210
Very much improved at Week 1610055
Much improved at Week 16136111
Minimally improved at Week 165884
No change at Week 162549
Minimally worse at Week 16523
Much worse at Week 1629
Very much worse at Week 1610
Very much improved at Week 2010661
Much improved at Week 20137110
Minimally improved at Week 205583
No change at Week 201949
Minimally worse at Week 20719
Much worse at Week 2029
Very much worse at Week 2010
Very much improved at Week 2412364
Much improved at Week 24123109
Minimally improved at Week 244886
No change at Week 242544
Minimally worse at Week 24619
Much worse at Week 2419
Very much worse at Week 2410
Very much improved at Week 2812771
Much improved at Week 28121104
Minimally improved at Week 284680
No change at Week 282448
Minimally worse at Week 28719
Much worse at Week 2819
Very much worse at Week 2810
Very much improved at Week 3214882
Much improved at Week 3210396
Minimally improved at Week 324281
No change at Week 322843
Minimally worse at Week 32420
Much worse at Week 3219
Very much worse at Week 3210
SecondaryChange From Baseline in Participant-reported Depressive Symptoms as Assessed by Patient Health Questionnaire (PHQ) 9-item Total Score

Change from baseline in participant-reported depressive symptoms as assessed by PHQ 9-item total score was reported. The PHQ-9 is a validated 9-item, patient-reported outcome (PRO) measure to assess depressive symptoms. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27).

Time frame:
Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Reported as:
Mean · Units on scale
Change From Baseline in Participant-reported Depressive Symptoms as Assessed by Patient Health Questionnaire (PHQ) 9-item Total Score
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 2-4.9 ± 4.90-3.1 ± 4.62
Week 4-6.7 ± 5.25-5.0 ± 5.06
Week 6-8.1 ± 5.37-6.1 ± 5.64
Week 8-8.9 ± 5.74-7.4 ± 5.58
Week 10-9.6 ± 5.37-8.4 ± 5.58
Week 12-9.8 ± 5.78-8.7 ± 5.65
Week 14-10.2 ± 5.49-8.5 ± 5.76
Week 16-10.5 ± 5.50-9.2 ± 5.77
Week 18-10.6 ± 5.79-9.3 ± 5.74
Week 20-10.4 ± 5.64-9.4 ± 5.97
Week 22-10.7 ± 5.74-9.5 ± 5.87
Week 24-10.6 ± 5.84-9.7 ± 6.08
Week 26-10.9 ± 5.88-9.7 ± 6.21
Week 28-10.9 ± 6.16-10.0 ± 6.23
Week 30-11.2 ± 6.39-10.1 ± 6.08
Week 32-11.4 ± 6.40-10.5 ± 6.01
SecondaryChange From Baseline in Participant-reported Depressive Symptoms as Assessed by PHQ 9-item Total Score at LOCF

Change from baseline in participant-reported depressive symptoms as assessed by PHQ 9-item total score at LOCF was reported. The PHQ-9 is a validated 9-item, PRO measure to assess depressive symptoms. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27). LOCF is defined as participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

Time frame:
Baseline, LOCF at Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Reported as:
Mean · Units on scale
Change From Baseline in Participant-reported Depressive Symptoms as Assessed by PHQ 9-item Total Score at LOCF
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 2-4.9 ± 4.90-3.1 ± 4.62
Week 4-6.6 ± 5.33-4.7 ± 5.06
Week 6-7.8 ± 5.51-5.6 ± 5.69
Week 8-8.5 ± 5.94-6.3 ± 5.86
Week 10-9.0 ± 5.75-7.0 ± 5.90
Week 12-9.1 ± 6.13-7.1 ± 6.07
Week 14-9.3 ± 5.93-6.9 ± 6.12
Week 16-9.6 ± 5.98-7.4 ± 6.20
Week 18-9.5 ± 6.26-7.3 ± 6.21
Week 20-9.4 ± 6.12-7.4 ± 6.32
Week 22-9.7 ± 6.27-7.5 ± 6.31
Week 24-9.5 ± 6.35-7.5 ± 6.47
Week 26-9.7 ± 6.46-7.5 ± 6.56
Week 28-9.7 ± 6.66-7.6 ± 6.64
Week 30-9.9 ± 6.85-7.6 ± 6.61
Week 32-10.1 ± 6.94-8.0 ± 6.70
SecondaryChange From Baseline in Participant-reported Functional Impairment and Associated Disability as Assessed by Sheehan Disability Scale (SDS) Total Score

Change from baseline in participant-reported functional impairment and associated disability as assessed by SDS total score was reported. The SDS is a validated PRO measure consisting of a 5-item questionnaire that has been widely used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a rating scale from 0 to 10. It also has 1 item assessing days lost from school or work and 1 item assessing days of underproductivity. The scores for the first 3 items are summed to create a total score of 0 to 30, where higher score indicates greater impairment. Scores \<=2 for each item and \<= 6 for the total score are considered functional remission.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on scale
Change From Baseline in Participant-reported Functional Impairment and Associated Disability as Assessed by Sheehan Disability Scale (SDS) Total Score
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 4-5.9 ± 6.58-4.1 ± 5.89
Week 8-8.6 ± 7.03-6.8 ± 7.63
Week 12-9.7 ± 7.54-8.6 ± 6.94
Week 16-10.6 ± 7.29-9.0 ± 7.50
Week 20-10.9 ± 7.57-9.0 ± 7.41
Week 24-11.2 ± 7.88-10.1 ± 7.76
Week 28-11.9 ± 7.84-10.8 ± 8.03
Week 32-12.6 ± 8.09-11.1 ± 8.06
SecondaryChange From Baseline in Participant-reported Functional Impairment and Associated Disability as Assessed by SDS Total Score at LOCF

Change from baseline in participant-reported functional impairment and associated disability as assessed by SDS total score at LOCF was reported. The SDS is a validated PRO measure consisting of a 5-item questionnaire for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a rating scale from 0 to 10. It also has 1 item assessing days lost from school or work and 1 item assessing days of underproductivity. The scores for the first 3 items are summed to create a total score of 0 to 30, where higher score indicates greater impairment. Scores \<=2 for each item and \<= 6 for the total score are considered functional remission. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

Time frame:
Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on scale
Change From Baseline in Participant-reported Functional Impairment and Associated Disability as Assessed by SDS Total Score at LOCF
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 4-5.9 ± 6.58-4.1 ± 5.89
Week 8-8.2 ± 7.06-5.8 ± 7.45
Week 12-9.0 ± 7.59-6.8 ± 7.59
Week 16-9.8 ± 7.47-7.0 ± 7.99
Week 20-9.9 ± 7.75-7.0 ± 7.97
Week 24-10.0 ± 8.13-7.6 ± 8.37
Week 28-10.4 ± 8.21-7.9 ± 8.69
Week 32-11.1 ± 8.56-8.2 ± 8.78
SecondaryChange From Baseline in Participant-reported Health-related Quality of Life (HRQoL) and Health Status as Assessed by 36-item Short-Form Health Survey (SF-36) Scale Score

Change from baseline in participant-reported HRQoL and health status as assessed by SF-36 scale score was reported. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using likert-type responses (for example: none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQoL, 100=best HRQoL. Higher scores indicate better health status.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on scale
Change From Baseline in Participant-reported Health-related Quality of Life (HRQoL) and Health Status as Assessed by 36-item Short-Form Health Survey (SF-36) Scale Score
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Physical Functioning Week 43.5 ± 7.162.2 ± 6.85
Physical Functioning Week 85.4 ± 7.643.8 ± 8.19
Physical Functioning Week 125.8 ± 8.294.7 ± 8.00
Physical Functioning Week 166.2 ± 8.365.2 ± 8.42
Physical Functioning Week 206.1 ± 8.625.1 ± 8.87
Physical Functioning Week 246.2 ± 9.015.9 ± 9.23
Physical Functioning Week 286.4 ± 8.686.2 ± 9.51
Physical Functioning Week 326.8 ± 8.796.4 ± 9.58
Role-Physical Week 45.7 ± 9.573.1 ± 9.75
Role-Physical Week 87.5 ± 10.496.1 ± 11.67
Role-Physical Week 128.8 ± 10.597.1 ± 11.38
Role-Physical Week 1610.0 ± 11.608.3 ± 12.47
Role-Physical Week 2010.0 ± 11.758.2 ± 12.34
Role-Physical Week 2410.4 ± 11.979.2 ± 12.50
Role-Physical Week 2810.9 ± 11.928.8 ± 12.62
Role-Physical Week 3211.7 ± 11.979.4 ± 12.39
Body Pain Week 43.7 ± 9.052.3 ± 8.50
Body Pain Week 84.5 ± 10.044.0 ± 8.85
Body Pain Week 125.1 ± 9.935.3 ± 9.71
Body Pain Week 165.6 ± 10.055.5 ± 10.52
Body Pain Week 205.7 ± 11.146.0 ± 10.41
Body Pain Week 246.2 ± 10.686.1 ± 10.64
Body Pain Week 286.2 ± 11.326.3 ± 11.34
Body Pain Week 326.7 ± 11.037.2 ± 11.62
General Health Week 45.3 ± 7.853.3 ± 7.45
General Health Week 87.2 ± 8.635.7 ± 8.50
General Health Week 127.9 ± 8.796.4 ± 9.02
General Health Week 168.8 ± 9.097.3 ± 9.55
General Health Week 209.0 ± 9.307.2 ± 9.71
General Health Week 249.5 ± 9.737.7 ± 10.05
General Health Week 2810.1 ± 9.718.8 ± 10.38
General Health Week 3210.6 ± 10.259.7 ± 10.33
Vitality Week 48.7 ± 9.135.2 ± 7.75
Vitality Week 811.3 ± 10.049.2 ± 9.44
Vitality Week 1212.4 ± 10.3610.8 ± 9.79
Vitality Week 1613.1 ± 10.6912.1 ± 9.88
Vitality Week 2013.2 ± 10.6712.6 ± 10.64
Vitality Week 2413.4 ± 10.8312.9 ± 11.26
Vitality Week 2814.2 ± 11.2513.9 ± 11.19
Vitality Week 3215.2 ± 11.6414.0 ± 11.34
Social Functioning Week 47.1 ± 10.325.0 ± 8.83
Social Functioning Week 811.2 ± 11.428.7 ± 9.59
Social Functioning Week 1212.4 ± 11.2910.2 ± 10.45
Social Functioning Week 1613.5 ± 10.9211.2 ± 11.24
Social Functioning Week 2013.6 ± 11.6511.7 ± 10.73
Social Functioning Week 2414.3 ± 11.5512.5 ± 11.75
Social Functioning Week 2815.3 ± 11.2613.3 ± 11.15
Social Functioning Week 3216.1 ± 11.3413.8 ± 11.47
Role-Emotional Week 48.6 ± 9.625.3 ± 9.53
Role-Emotional Week 812.7 ± 10.6710.1 ± 11.30
Role-Emotional Week 1213.8 ± 10.7012.2 ± 11.48
Role-Emotional Week 1615.4 ± 11.3013.2 ± 12.07
Role-Emotional Week 2015.8 ± 11.2613.4 ± 11.14
Role-Emotional Week 2416.0 ± 11.7914.7 ± 11.71
Role-Emotional Week 2817.3 ± 12.4415.0 ± 11.58
Role-Emotional Week 3218.1 ± 12.4914.9 ± 12.62
Mental Health Week 49.8 ± 9.776.7 ± 9.34
Mental Health Week 813.5 ± 10.3711.6 ± 10.78
Mental Health Week 1215.0 ± 10.5013.3 ± 10.84
Mental Health Week 1616.1 ± 11.0414.3 ± 11.01
Mental Health Week 2016.5 ± 10.9014.7 ± 11.36
Mental Health Week 2416.6 ± 11.6915.3 ± 11.45
Mental Health Week 2817.6 ± 11.4016.5 ± 12.16
Mental Health Week 3218.4 ± 11.8917.0 ± 12.05
SecondaryChange From Baseline in Participant-reported HRQoL and Health Status as Assessed by SF-36 Scale Score at LOCF

Change from baseline in participant-reported HRQoL and health status as assessed by SF-36 domain scores at LOCF was reported. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using likert-type responses (for example: none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQoL, 100=best HRQoL. Higher scores indicate better health status. LOCF is defined as participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

Time frame:
Baseline, LOCF at Weeks 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on scale
Change From Baseline in Participant-reported HRQoL and Health Status as Assessed by SF-36 Scale Score at LOCF
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Physical Functioning Week 85.1 ± 7.613.2 ± 8.15
Physical Functioning Week 125.3 ± 8.223.9 ± 7.96
Physical Functioning Week 165.6 ± 8.334.2 ± 8.27
Physical Functioning Week 205.5 ± 8.634.0 ± 8.48
Physical Functioning Week 245.6 ± 8.834.4 ± 8.84
Physical Functioning Week 285.6 ± 8.714.5 ± 8.97
Physical Functioning Week 326.0 ± 8.774.6 ± 9.05
Role-Physical Week 87.4 ± 10.515.3 ± 11.50
Role-Physical Week 128.3 ± 10.875.7 ± 11.31
Role-Physical Week 169.3 ± 11.496.2 ± 12.23
Role-Physical Week 209.1 ± 11.696.3 ± 12.09
Role-Physical Week 249.2 ± 11.936.9 ± 12.48
Role-Physical Week 289.4 ± 12.006.8 ± 12.36
Role-Physical Week 3210.2 ± 12.217.2 ± 12.29
Body Pain Week 84.4 ± 9.843.5 ± 8.79
Body Pain Week 124.8 ± 9.994.2 ± 9.51
Body Pain Week 165.2 ± 10.144.3 ± 10.02
Body Pain Week 205.2 ± 10.854.5 ± 10.05
Body Pain Week 245.6 ± 10.454.4 ± 10.26
Body Pain Week 285.4 ± 11.014.5 ± 10.78
Body Pain Week 326.0 ± 10.935.0 ± 11.10
General Health Week 86.9 ± 8.854.9 ± 8.19
General Health Week 127.4 ± 9.195.1 ± 8.68
General Health Week 168.0 ± 9.415.6 ± 9.20
General Health Week 208.1 ± 9.605.5 ± 9.37
General Health Week 248.2 ± 10.085.6 ± 9.57
General Health Week 288.6 ± 10.196.1 ± 10.01
General Health Week 329.2 ± 10.786.7 ± 10.18
Vitality Week 811.1 ± 10.087.8 ± 9.46
Vitality Week 1211.7 ± 10.488.7 ± 9.98
Vitality Week 1612.3 ± 10.819.5 ± 10.26
Vitality Week 2012.3 ± 10.949.6 ± 10.77
Vitality Week 2412.2 ± 11.049.6 ± 11.34
Vitality Week 2812.8 ± 11.4310.1 ± 11.53
Vitality Week 3213.8 ± 11.9910.4 ± 11.65
Social Functioning Week 810.7 ± 11.317.6 ± 9.72
Social Functioning Week 1211.4 ± 11.298.6 ± 10.47
Social Functioning Week 1612.2 ± 11.249.0 ± 11.22
Social Functioning Week 2012.3 ± 11.919.1 ± 10.92
Social Functioning Week 2412.7 ± 11.819.5 ± 11.63
Social Functioning Week 2813.0 ± 12.099.8 ± 11.49
Social Functioning Week 3214.0 ± 12.3510.3 ± 11.71
Role-Emotional Week 812.0 ± 10.758.6 ± 11.30
Role-Emotional Week 1212.7 ± 10.899.8 ± 11.82
Role-Emotional Week 1614.2 ± 11.5310.3 ± 12.32
Role-Emotional Week 2014.3 ± 11.7710.4 ± 11.67
Role-Emotional Week 2414.3 ± 12.1511.2 ± 12.22
Role-Emotional Week 2815.2 ± 12.9111.2 ± 12.30
Role-Emotional Week 3216.0 ± 13.1611.2 ± 12.96
Mental Health Week 812.9 ± 10.769.8 ± 11.04
Mental Health Week 1214.0 ± 11.0910.6 ± 11.44
Mental Health Week 1614.7 ± 11.6310.9 ± 11.85
Mental Health Week 2015.0 ± 11.6411.2 ± 12.07
Mental Health Week 2414.8 ± 12.2411.5 ± 12.23
Mental Health Week 2815.5 ± 12.3512.2 ± 13.01
Mental Health Week 3216.3 ± 12.9012.6 ± 13.08
SecondaryChange From Baseline in Participant-reported Quality of Life as Assessed by Quality of Life in Depression Scale (QLDS) Total Score

Change from baseline in participant-reported quality of life as assessed by QLDS total score was reported. The QLDS is a disease-specific validated PRO measure which assesses the impact that depression has on a participant's quality of life. It is a 34-item self-rated questionnaire which consists of dichotomous response questions, with the response being either True/Not True. Each statement on the QLDS is given a score of "1" or "0". A score of "1" is indicative of adverse quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on Scale
Change From Baseline in Participant-reported Quality of Life as Assessed by Quality of Life in Depression Scale (QLDS) Total Score
Units on ScaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 4-8.9 ± 8.83-5.6 ± 7.43
Week 8-12.0 ± 9.36-9.1 ± 9.31
Week 12-13.5 ± 9.30-10.9 ± 9.52
Week 16-14.2 ± 9.39-11.6 ± 9.39
Week 20-14.3 ± 9.50-12.1 ± 9.74
Week 24-14.9 ± 9.44-12.8 ± 9.64
Week 28-15.6 ± 9.42-13.7 ± 9.51
Week 32-16.0 ± 9.55-14.2 ± 9.96
SecondaryChange From Baseline in Participant-reported Quality of Life as Assessed by QLDS Total Score at LOCF

Change from baseline in participant-reported quality of life as assessed by QLDS total score at LOCF was reported. The QLDS is a disease-specific validated PRO measure which assesses the impact that depression has on a participant's quality of life. It is a 34-item self-rated questionnaire which consists of dichotomous response questions, with the response being either True/Not True. Each statement on the QLDS is given a score of "1" or "0". A score of "1" is indicative of adverse quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

Time frame:
Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on Scale
Change From Baseline in Participant-reported Quality of Life as Assessed by QLDS Total Score at LOCF
Units on ScaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 4-8.9 ± 8.83-5.6 ± 7.43
Week 8-11.3 ± 9.59-8.1 ± 9.22
Week 12-12.3 ± 9.73-9.0 ± 9.62
Week 16-13.0 ± 9.86-9.3 ± 9.80
Week 20-13.0 ± 9.93-9.5 ± 10.02
Week 24-13.3 ± 9.98-9.8 ± 10.18
Week 28-13.6 ± 10.06-10.3 ± 10.26
Week 32-14.1 ± 10.29-10.5 ± 10.59
SecondaryChange From Baseline in Participant-reported Health-related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score: Health Status Index

Change from baseline in participant-reported health-related quality of Life as assessed by EQ-5D-5L score: health status index was reported. The EQ-5D-5L is a standardized 2-part instrument used to measure health outcomes, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ-VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today." Responses were used to generate health status index which ranges from 0 (dead) and 1 (full health), a lower score indicates worse health.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on Scale
Change From Baseline in Participant-reported Health-related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score: Health Status Index
Units on ScaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 40.177 ± 0.23540.124 ± 0.2280
Week 80.234 ± 0.26550.206 ± 0.2463
Week 120.276 ± 0.24050.227 ± 0.2367
Week 160.284 ± 0.24450.232 ± 0.2431
Week 200.294 ± 0.23990.238 ± 0.2423
Week 240.297 ± 0.24980.259 ± 0.2489
Week 280.303 ± 0.25840.262 ± 0.2492
Week 320.317 ± 0.26360.279 ± 0.2581
SecondaryChange From Baseline in Participant-reported Health-related Quality of Life Group, as Assessed by EQ-5D-5L Score: Health Status Index at LOCF

Change from baseline in participant-reported health-related quality of Life as assessed by EQ-5D-5L score: health status index at LOCF was reported. The EQ-5D-5L is a standardized 2-part instrument used to measure health outcomes, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ-VAS. The EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today." LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

Time frame:
Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on Scale
Change From Baseline in Participant-reported Health-related Quality of Life Group, as Assessed by EQ-5D-5L Score: Health Status Index at LOCF
Units on ScaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 40.177 ± 0.23540.124 ± 0.2280
Week 80.221 ± 0.26810.175 ± 0.2510
Week 120.247 ± 0.25520.187 ± 0.2523
Week 160.255 ± 0.25800.188 ± 0.2595
Week 200.261 ± 0.26000.187 ± 0.2590
Week 240.264 ± 0.26270.196 ± 0.2671
Week 280.266 ± 0.27390.195 ± 0.2664
Week 320.280 ± 0.28060.207 ± 0.2739
SecondaryChange From Baseline in Participant-reported Health Status as Assessed by EQ-5D-5L Score: VAS

Change from baseline in participant-reported health status as assessed by EQ-5D-5L Score: VAS was reported. The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on Scale
Change From Baseline in Participant-reported Health Status as Assessed by EQ-5D-5L Score: VAS
Units on ScaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 413.3 ± 18.439.7 ± 17.83
Week 818.9 ± 19.8416.1 ± 19.64
Week 1220.9 ± 20.9817.2 ± 20.73
Week 1621.9 ± 20.1420.2 ± 22.14
Week 2022.3 ± 21.2019.6 ± 21.59
Week 2423.6 ± 20.9521.8 ± 21.60
Week 2825.2 ± 20.9523.2 ± 22.11
Week 3224.9 ± 21.6524.5 ± 22.64
SecondaryChange From Baseline in Participant-reported Health Status as Assessed by EQ-5D-5L Score: VAS at LOCF

Change from baseline in participant-reported health status as assessed by EQ-5D-5L score: VAS at LOCF was reported. The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

Time frame:
Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on Scale
Change From Baseline in Participant-reported Health Status as Assessed by EQ-5D-5L Score: VAS at LOCF
Units on ScaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Week 413.3 ± 18.439.7 ± 17.83
Week 818.2 ± 19.9414.0 ± 20.42
Week 1219.4 ± 21.0414.4 ± 21.19
Week 1620.2 ± 20.3716.1 ± 22.42
Week 2020.4 ± 21.3415.4 ± 22.19
Week 2421.3 ± 21.3416.9 ± 22.64
Week 2821.9 ± 21.7817.3 ± 23.10
Week 3222.3 ± 22.4718.0 ± 23.59
SecondaryChange From Baseline in Participant-reported Work Productivity as Assessed by Work Productivity and Activity Impairment (WPAI): Depression Questionnaire

Change from baseline in participant-reported work productivity as assessed by WPAI: depression questionnaire was reported. The WPAI-D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores were derived only for respondents who were working (should be missing for non-working), but the last score was applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on scale
Change From Baseline in Participant-reported Work Productivity as Assessed by Work Productivity and Activity Impairment (WPAI): Depression Questionnaire
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Absenteeism Week 4-11.95 ± 20.745-8.37 ± 25.790
Absenteeism Week 8-19.02 ± 30.205-13.62 ± 31.059
Absenteeism Week 12-21.87 ± 34.711-17.25 ± 31.340
Absenteeism Week 16-22.85 ± 33.023-14.24 ± 37.823
Absenteeism Week 20-27.88 ± 32.107-18.70 ± 35.310
Absenteeism Week 24-26.83 ± 32.909-21.03 ± 34.459
Absenteeism Week 28-27.16 ± 35.825-17.90 ± 31.254
Absenteeism Week 32-28.90 ± 32.066-16.68 ± 29.394
Presenteeism Week 4-21.75 ± 25.558-9.13 ± 21.948
Presenteeism Week 8-31.70 ± 25.144-16.86 ± 27.140
Presenteeism Week 12-35.46 ± 27.998-23.22 ± 29.942
Presenteeism Week 16-36.96 ± 28.556-24.50 ± 31.898
Presenteeism Week 20-39.80 ± 26.263-26.34 ± 33.389
Presenteeism Week 24-42.83 ± 27.332-31.60 ± 30.922
Presenteeism Week 28-43.00 ± 28.762-33.29 ± 34.445
Presenteeism Week 32-47.58 ± 26.691-33.88 ± 33.621
Work productivity loss Week 4-20.94 ± 25.759-9.46 ± 23.374
Work productivity loss Week 8-32.91 ± 26.244-18.21 ± 29.156
Work productivity loss Week 12-36.68 ± 29.247-25.62 ± 35.135
Work productivity loss Week 16-38.13 ± 30.490-24.50 ± 34.089
Work productivity loss Week 20-41.11 ± 28.643-26.57 ± 32.885
Work productivity loss Week 24-45.31 ± 29.000-30.63 ± 34.087
Work productivity loss Week 28-44.40 ± 32.098-32.61 ± 33.836
Work productivity loss Week 32-50.20 ± 29.176-35.48 ± 35.915
Activity Impairment Week 4-20.29 ± 23.702-13.43 ± 20.846
Activity Impairment Week 8-30.31 ± 27.410-24.25 ± 24.187
Activity Impairment Week 12-33.96 ± 27.218-28.28 ± 25.555
Activity Impairment Week 16-35.07 ± 27.291-30.95 ± 27.444
Activity Impairment Week 20-33.88 ± 28.770-30.93 ± 27.698
Activity Impairment Week 24-36.69 ± 29.742-36.84 ± 27.000
Activity Impairment Week 28-40.00 ± 29.828-37.62 ± 28.500
Activity Impairment Week 32-41.92 ± 30.299-39.59 ± 27.190
SecondaryChange From Baseline in Participant-reported Work Productivity as Assessed by WPAI: Depression Questionnaire at LOCF

Change from baseline in participant-reported work productivity as assessed by WPAI: depression questionnaire at LOCF was reported. The WPAI-D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores were derived only for respondents who were working (should be missing for non-working), but the last score was applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.

Time frame:
Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Mean · Units on scale
Change From Baseline in Participant-reported Work Productivity as Assessed by WPAI: Depression Questionnaire at LOCF
Units on scaleEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Absenteeism Week 4-11.95 ± 20.745-8.37 ± 25.790
Absenteeism Week 8-18.28 ± 29.417-12.38 ± 30.369
Absenteeism Week 12-20.23 ± 33.590-15.17 ± 31.835
Absenteeism Week 16-21.35 ± 31.806-14.14 ± 37.534
Absenteeism Week 20-25.45 ± 31.628-16.04 ± 37.769
Absenteeism Week 24-24.41 ± 32.403-16.28 ± 37.672
Absenteeism Week 28-23.88 ± 34.623-14.14 ± 35.849
Absenteeism Week 32-26.10 ± 31.903-13.90 ± 36.104
Presenteeism Week 4-21.75 ± 25.558-9.13 ± 21.948
Presenteeism Week 8-29.45 ± 26.437-14.84 ± 27.067
Presenteeism Week 12-33.57 ± 28.745-17.44 ± 29.997
Presenteeism Week 16-35.00 ± 29.075-19.84 ± 31.322
Presenteeism Week 20-36.08 ± 28.598-21.41 ± 32.862
Presenteeism Week 24-36.87 ± 29.641-22.19 ± 32.189
Presenteeism Week 28-37.40 ± 30.924-23.83 ± 34.757
Presenteeism Week 32-40.53 ± 30.700-23.44 ± 35.526
Work productivity loss Week 4-20.94 ± 25.759-9.46 ± 23.374
Work productivity loss Week 8-30.59 ± 26.789-15.35 ± 30.059
Work productivity loss Week 12-34.46 ± 29.333-19.27 ± 33.905
Work productivity loss Week 16-36.35 ± 30.531-20.75 ± 33.545
Work productivity loss Week 20-37.59 ± 30.354-22.58 ± 34.117
Work productivity loss Week 24-39.02 ± 31.482-22.54 ± 34.635
Work productivity loss Week 28-39.09 ± 33.271-23.85 ± 35.152
Work productivity loss Week 32-43.42 ± 32.638-24.89 ± 37.870
Activity Impairment Week 4-20.29 ± 23.702-13.43 ± 20.846
Activity Impairment Week 8-28.84 ± 27.412-20.39 ± 24.599
Activity Impairment Week 12-31.10 ± 27.778-22.81 ± 26.264
Activity Impairment Week 16-31.84 ± 28.413-23.68 ± 28.014
Activity Impairment Week 20-30.84 ± 29.983-23.62 ± 28.185
Activity Impairment Week 24-32.45 ± 31.207-26.71 ± 28.821
Activity Impairment Week 28-34.87 ± 31.804-27.07 ± 29.965
Activity Impairment Week 32-36.65 ± 32.357-28.40 ± 29.930
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs were those events if they started after administration of the first dose until 14 days after the last dose of study medication for other TEAEs except serious; and first dose until 30 days after the last dose of study medication for serious TEAEs.

Time frame:
Up to Week 35
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Number of Participants With Treatment-emergent Adverse Events (TEAEs)307262
SecondaryNumber of Participants With TEAEs of Special Interest

Number of participants with TEAEs of special interest were reported. It included significant TEAEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Events such as sedation, depersonalization/derealization disorder, depression suicidal, aggression, allergic cystitis, cholestasis and jaundice of hepatic origin, and many more were considered as TEAEs of special interest.

Time frame:
Up to Week 35
Reported as:
Count of participants · Participants
Number of Participants With TEAEs of Special Interest
ParticipantsEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Number of Participants With TEAEs of Special Interest223140
SecondaryNumber of Participants With Suicidal Ideation or Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score

Number of participants with suicidal ideation or behavior as assessed by C-SSRS score was reported. The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Suicidal ideation consists of 5 items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, and active suicidal ideation with specific plan and intent. Suicidal behavior consists of 5 items: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt (non-fatal), and completed suicide. The maximum score (from the 10 categories) assigned for each participant was summarized into one of three broad categories: No suicidal ideation or behavior (0), Suicidal ideation (1 - 5), Suicidal behavior (6 - 10). Total score ranges from 1 to 10. Higher scores indicate more severe suicidal ideation and behavior.

Time frame:
Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation or Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score
ParticipantsEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
Suicidal Ideation Week 12225
Suicidal Behavior Week 100
Suicidal Ideation Week 22132
Suicidal Behavior Week 201
Suicidal Ideation Week 31917
Suicidal Behavior Week 300
Suicidal Ideation Week 42227
Suicidal Behavior Week 400
Suicidal Ideation Week 82118
Suicidal Behavior Week 800
Suicidal Ideation Week 121314
Suicidal Behavior Week 1200
Suicidal Ideation Week 161212
Suicidal Behavior Week 1611
Suicidal Ideation Week 201514
Suicidal Behavior Week 2000
Suicidal Ideation Week 24149
Suicidal Behavior Week 2400
Suicidal Ideation Week 2885
Suicidal Behavior Week 2800
Suicidal Ideation Week 3274
Suicidal Behavior Week 3201

Adverse events

Collected over All-cause mortality and serious adverse events: until 30 days after last dose (up to Week 35); other AEs: until 14 days after last dose (up to Week 33). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esketamine Nasal Spray + Oral Antidepressant (AD)1/334 (0.3%)19/334 (5.7%)289/334 (86.5%)
Quetiapine Extended Release (XR) + Oral AD1/336 (0.3%)17/336 (5.1%)216/336 (64.3%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
DepressionPsychiatric disorders2/3343/336
Suicidal ideationPsychiatric disorders1/3343/336
Somatic symptom disorderPsychiatric disorders2/3340/336
Suicide attemptPsychiatric disorders2/3341/336
AnxietyPsychiatric disorders0/3342/336
Acute coronary syndromeCardiac disorders1/3340/336
Atrial fibrillationCardiac disorders1/3340/336
Retinal detachmentEye disorders1/3340/336
PancreatitisGastrointestinal disorders1/3340/336
DeathGeneral disorders1/3340/336
Most frequent other events
Showing 10 of 20
Most frequent other events
EventEsketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral AD
DizzinessNervous system disorders156/33428/336
NauseaGastrointestinal disorders98/33412/336
DissociationPsychiatric disorders94/3342/336
HeadacheNervous system disorders82/33443/336
SomnolenceNervous system disorders50/33478/336
VertigoEar and labyrinth disorders63/3343/336
Weight increasedInvestigations9/33442/336
DysgeusiaNervous system disorders40/3341/336
ParaesthesiaNervous system disorders37/3342/336
VomitingGastrointestinal disorders36/3345/336

Baseline characteristics

Age, Continuous
Age, Continuous(years)Esketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral ADTotal
Mean44.3 ± 13.645.7 ± 13.3845 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)Esketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral ADTotal
Female225222447
Male111118229
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Esketamine Nasal Spray + Oral Antidepressant (AD)Quetiapine Extended Release (XR) + Oral ADTotal
American Indian or Alaska Native000
Asian91019
Native Hawaiian or Other Pacific Islander000
Black or African American5712
White137152289
More than one race000
Unknown or Not Reported185171356
08

Study locations

171 sites
  • FunDaMos
    Ciudad Autonoma de Buenos Aires, C1405BOA, Argentina
  • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
    Ciudad Autónoma De Buenos Aires, C1133AAH, Argentina
  • CEN Consultorios Especializados en Neurociencias
    Cordoba, 5000FJF, Argentina
  • Fundacion Lennox
    Cordoba, 5000, Argentina
  • Instituto Medico DAMIC
    Cordoba, X5003DCE, Argentina
  • Sanatorio Prof Leon S Morra S A
    Cordoba, X5009BIN, Argentina
  • Instituto de Neurociencias San Agustin
    La Plata, 1900, Argentina
  • C I A P Centro de investigacion y Asistencia en Psiquiatria
    Rosario, 2000, Argentina
  • Medical University Graz
    Graz, 8036, Austria
  • Schmitz and Schmitz
    Vienna, 1010, Austria
  • Medical University Vienna MUV
    Vienna, 1090, Austria
  • Anima
    Alken, 3570, Belgium
  • Pz Duffel
    Duffel, 2570, Belgium
  • Clinique Psychiatrique des Frères Alexiens
    Henri Chapelle, 4841, Belgium
  • Sint-Franciskusziekenhuis
    Heusden-Zolder, 3550, Belgium
  • ARIADNE
    Lede, 9340, Belgium
  • CHU de Liege
    Liege, 4000, Belgium
  • CPN - Centro de Pesquisa em Neurociências Ltda
    Belo Horizonte, 30150-270, Brazil
  • Trial Tech Tecnologia em Pesquisas com Medicamentos
    Curitiba, 80240-280, Brazil
  • Ruschel Medicina e Pesquisa Clínica Ltda
    Rio de Janeiro, 22270 060, Brazil
  • C J S Carvalho & Carvalho LTDA (Viver - Centro De Desospitalizacao Humana)
    Sao Paulo, 04020-060, Brazil
  • BR Trials
    Sao Paulo, 05003-090, Brazil
  • State Psychiatric Hospital Kardzhali
    Kardzhali, 6600, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', EAD
    Pleven, 5800, Bulgaria
  • Mental Health Center - Plovdiv
    Plovdiv, 4002, Bulgaria
  • Mental Health Center - Rousse
    Rousse, 7003, Bulgaria
  • Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum
    Sofia, 1113, Bulgaria
  • MHC - Sofia, EOOD
    Sofia, 1202, Bulgaria
  • Centre for Mental Health Prof.N.Shipkovenski EOOD
    Sofia, 1377, Bulgaria
  • University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
    Sofia, 1431, Bulgaria
  • Psychiatricka ambulance Saint Anne s.r.o.
    Brno, 60200, Czechia
  • Psychiatricka ambulance, MUDr. Marta Holanova
    Brno, 61500, Czechia
  • NeuropsychiatrieHK, s.r.o.
    Hradec Kralove-Vekose, 50341, Czechia
  • A Shine S R O
    Plzen, 31200, Czechia
  • Institut Neuropsychiatricke pece
    Prague, 18600, Czechia
  • Clintrial s r o
    Praha 10, 10000, Czechia
  • AD71 s.r.o.
    Praha 10, 109 00, Czechia
  • Medical Services Prague S R O
    Praha 6, 16000, Czechia
  • Aalborg University Hospital
    Aalborg, 9000, Denmark
  • Psykiatrien i Region Syddanmark
    Esbjerg N, 6715, Denmark
  • Mederon LTD at ARTES
    Helsinki, 00270, Finland
  • Psykiatrinen Palvelukeskus Solvum Oy
    Helsinki, 120, Finland
  • Savon Psykiatripalvelu
    Kuopio, 70110, Finland
  • Universitaetsklinikum der RWTH Aachen
    Aachen, 52074, Germany
  • Rheinhessen Fachklinik Alzey
    Alzey, 55232, Germany
  • Emovis GmbH
    Berlin, 10629, Germany
  • Charite Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Medizinisches Versorgungszentrum LiO GmbH
    Berlin, 12209, Germany
  • Alexander Schulze - Germany
    Berlin, 13156, Germany
  • Praxis Dr. med. Kirsten Hahn
    Berlin, 13187, Germany
  • Vivantes Klinikum Spandau
    Berlin, 13585, Germany
  • Universitatsklinikum Bonn
    Bonn, 53105, Germany
  • Klinikum Chemnitz gGmbH
    Chemnitz, 09131, Germany
  • Carl-Thiem-Klinikum Cottbus gGmbH
    Cottbus, 3048, Germany
  • Klinikum Dortmund gGmbH
    Dortmund, 44287, Germany
  • Universitatsklinikum Carl Gustav Carcus Dresden
    Dresden, 01307, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt Am Main, 60528, Germany
  • Universitätsklinikum Freiburg - Abteilung für Psychiatrie u. Psychotherapie mit Poliklinik
    Freiburg, 79104, Germany
  • SRH Waldklinikum Gera GmbH
    Gera, 7548, Germany
  • Georg August Universitat Universitatsmedizin Gottingen
    Gottingen, 37075, Germany
  • Evangelisches Krankenhaus Bethanien gGmbH
    Greifswald, 17489, Germany
  • Universitaetsklinik Hamburg-Eppendorf
    Hamburg, 20251, Germany
  • Klinische Forschung Hamburg
    Hamburg, 20253, Germany
  • Klinische Forschung Hannover-Mitte GmbH
    Hannover, 30159, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universität Heidelberg
    Heidelberg, 69115, Germany
  • Oberhavel Kliniken GmbH
    Hennigsdorf, 16761, Germany
  • Universitätsklinikum des Saarlandes
    Homburg, 66421, Germany
  • Universitatsklinikum Jena
    Jena, 7743, Germany
  • Panakeia - Arzneimittelforschung GmbH
    Leipzig, 04275, Germany
  • Universitaetsklinikum Magdeburg A.oe.R
    Magdeburg, 39120, Germany
  • Universitatsmedizin der Johannes Gutenberg Universitat Mainz
    Mainz, 55131, Germany
  • Pharmakologisches Studienzentrum Chemnitz GmbH
    Mittweida, 09648, Germany
  • Universitatsklinikum Munster
    Munster, 48147, Germany
  • Ruppiner Kliniken
    Neuruppin, 16816, Germany
  • Praxis Prof. Steinwachs
    Nurnberg, 90402, Germany
  • Johanniter Krankenhaus Oberhausen
    Oberhausen, 46145, Germany
  • Danuvius Klinik Pfaffenhofen Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik
    Pfaffenhofen, 85276, Germany
  • Somni Bene GmbH
    Schwerin, 19053, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • Klinikum der Hansestadt Stralsund GmbH-Ambulanz-Klinik für Psychiatrie und Psychotherapie - Germany
    Stralsund, 18437, Germany
  • Aiginition Hospital of Athens
    Athens, 11528, Greece
  • 'Dafni' Psychiatric Hospital of Attica
    Athens, 124 62, Greece
  • Venizeleio General Hospital
    Crete, 71409, Greece
  • Psychiatric Clinic 'Agios Charalampos'
    Heraklion, 71305, Greece
  • University General Hospital of Ioannina
    Ioannina, 45110, Greece
  • University General Hospital of Rio Patras
    Patras, 26504, Greece
  • 424 Military Hospital of Thessaloniki
    Thessaloniki, 54636, Greece
  • Psychiatric Hospital of Thessaloniki
    Thessaloniki, 56430, Greece
  • G Papanikolaou Hospital of Thessaloniki
    Thessaloniki, 57010, Greece
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Eszak Kozep budai Centrum Uj Szent Janos Korhaz es Szakrendelo Budai Csaladkozpontu
    Budapest, 1125, Hungary
  • Processus Kft
    Budapest, 1137, Hungary
  • Debreceni Egyetem, Kenézy Gyula Egyetemi Oktatókórház
    Debrecen, 4031, Hungary
  • Bugat Pal Korhaz
    Gyongyos, 3200, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Gyor, H-9024, Hungary
  • Bács-Kiskun Megyei Kórház a Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza
    Kalocsa, 6300, Hungary
  • Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz
    Nyiregyhaza, 4400, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pecs, 7623, Hungary
  • Rambam Medical Center
    Haifa, 3109601, Israel

Showing the first 100 of 171 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jan 2022, 16 months.

Results were first posted in Feb 2023, 1 year after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 16 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2020
First posted
Apr 8, 2020
StartActual
Aug 21, 2020
Primary completionActual
Jan 20, 2022
CompletionActual
Jul 15, 2022
Results first posted
Feb 15, 2023
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04338321
Responsible party
Sponsor
First posted
Apr 8, 2020
Start date
Aug 21, 2020
Primary completion
Jan 20, 2022
Completion
Jul 15, 2022
Results posted
Feb 15, 2023
Last update
Apr 29, 2025

Study contacts

Janssen-Cilag International NV Clinical Trials
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion